Cell:免疫细胞“起内讧”或促进胰腺癌恶化

2016-08-27 佚名 生物谷

图片来源:medicalxpress.com日前一项刊登于国际杂志Cell上的一项研究报告中,来自纽约大学医学中心的研究人员通过研究发现,不同类型细胞间的内部冲突或可帮助解释为何免疫系统会奋力识别并且攻击胰腺癌,而遏制这场内讧或许就可以开发出潜在有效的胰腺癌新型疗法。 文章中研究者描述了一种名为“γδT细胞”的特殊类型的免疫细胞,他们发现这类免疫细胞可以帮助抑制其它抵御肿瘤的T细胞进入到胰腺肿瘤

图片来源:medicalxpress.com

日前一项刊登于国际杂志Cell上的一项研究报告中,来自纽约大学医学中心的研究人员通过研究发现,不同类型细胞间的内部冲突或可帮助解释为何免疫系统会奋力识别并且攻击胰腺癌,而遏制这场内讧或许就可以开发出潜在有效的胰腺癌新型疗法。

文章中研究者描述了一种名为“γδT细胞”的特殊类型的免疫细胞,他们发现这类免疫细胞可以帮助抑制其它抵御肿瘤的T细胞进入到胰腺肿瘤内部,如果没有γδT细胞的干预,CD4和CD8细胞就会不断增值并且主动攻击肿瘤,但不幸的是,免疫系统能够产生大量的促肿瘤γδT细胞深入到肿瘤中,并且干扰免疫细胞对肿瘤的攻击。

免疫疗法近年来取得了巨大的进步,即激活患者自身的免疫系统来抵御癌症,从而增强CD4或CD8细胞的活性,本文研究则表明,这种免疫疗法或许就可以靶向应用于胰腺癌的治疗中,除非γδT细胞被阻断,不然CD4和CD8细胞就不能正常发挥功能去遏制癌症发展。研究者George Miller博士指出,标准的免疫疗法或许对胰腺癌并不奏效,尤其是致死性的胰腺癌,如今我们获取了更多信息来解释其原因,机体主要的抗肿瘤防御机制或许在胰腺癌面前完全没有作用。

Miller的研究重点关注于胰腺导管腺癌(PDA),这种类型的癌症总是致命性的,在过去20年里随着现代疗法的引入患者的总体生存率发生了明显的改善,个体在被诊断为任何一种类型的胰腺癌后仅有8%的患者能够存活5年。γδT细胞在胰腺导管腺癌中水平非常高,其平均大约占到了T细胞组分的40%,研究者认为,γδT细胞在胰腺癌的形成促进过程中扮演着重要的角色,独立实验结果表明,仅有γδT细胞并不会促进肿瘤生长,其会抑制其它抵御肿瘤的免疫细胞发挥作用。

研究者指出,这项研究阐明了机体免疫系统的复杂性,促进胰腺肿瘤未被抑制的γδT细胞被认为可以抵御其它类型的癌症,比如黑色素瘤,一些肾癌及结肠癌等;并不是所有的免疫细胞在不同癌症中都扮演着相同的角色,而且有时候免疫细胞之间还会起内讧。本文研究对于后期开发胰腺癌的新型诊断措施和治疗手段提供了一定的思路和研究基础,研究者希望后期可以进行更为深入的研究来继续探索。

原始出处

Donnele Daley7, Constantinos Pantelis Zambirinis7, Lena Seifert7, Neha Akkad, Navyatha Mohan, Gregor Werba, Rocky Barilla, Alejandro Torres-Hernandez, Mautin Hundeyin, Vishnu Raj Kumar Mani, Antonina Avanzi, Daniel Tippens, Rajkishen Narayanan, Jung-Eun Jang, Elliot Newman, Venu Gopal Pillarisetty, Michael Loran Dustin, Dafna Bar-Sagi, Cristina Hajdu, George Miller8.γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.Cell.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959783, encodeId=6cae1959e8336, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 21 08:47:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869524, encodeId=06ce1869524f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 14 09:47:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106717, encodeId=68fa106e1739, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:02:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106657, encodeId=c35a10665e89, content=新理念,值得重视!值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Mon Aug 29 08:04:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106294, encodeId=b8c410629491, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Sun Aug 28 12:37:00 CST 2016, time=2016-08-28, status=1, ipAttribution=)]
    2017-04-21 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959783, encodeId=6cae1959e8336, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 21 08:47:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869524, encodeId=06ce1869524f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 14 09:47:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106717, encodeId=68fa106e1739, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:02:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106657, encodeId=c35a10665e89, content=新理念,值得重视!值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Mon Aug 29 08:04:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106294, encodeId=b8c410629491, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Sun Aug 28 12:37:00 CST 2016, time=2016-08-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959783, encodeId=6cae1959e8336, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 21 08:47:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869524, encodeId=06ce1869524f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 14 09:47:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106717, encodeId=68fa106e1739, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:02:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106657, encodeId=c35a10665e89, content=新理念,值得重视!值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Mon Aug 29 08:04:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106294, encodeId=b8c410629491, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Sun Aug 28 12:37:00 CST 2016, time=2016-08-28, status=1, ipAttribution=)]
    2016-08-29 医路开来

    学习啦,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1959783, encodeId=6cae1959e8336, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 21 08:47:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869524, encodeId=06ce1869524f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 14 09:47:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106717, encodeId=68fa106e1739, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:02:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106657, encodeId=c35a10665e89, content=新理念,值得重视!值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Mon Aug 29 08:04:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106294, encodeId=b8c410629491, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Sun Aug 28 12:37:00 CST 2016, time=2016-08-28, status=1, ipAttribution=)]
    2016-08-29 zibozhouping

    新理念,值得重视!值得学习。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1959783, encodeId=6cae1959e8336, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 21 08:47:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869524, encodeId=06ce1869524f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Mar 14 09:47:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106717, encodeId=68fa106e1739, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:02:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106657, encodeId=c35a10665e89, content=新理念,值得重视!值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Mon Aug 29 08:04:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106294, encodeId=b8c410629491, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Sun Aug 28 12:37:00 CST 2016, time=2016-08-28, status=1, ipAttribution=)]
    2016-08-28 Guoxj3234

    学习起来

    0

相关资讯

Cell:固有免疫细胞在感染发生前就已做好充分准备

在一项新的研究中,通过使用强大的基因组技术,来自美国国家关节炎、肌肉骨骼与皮肤疾病研究所(National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIAMS)等多家机构的研究人员发现被称作固有淋巴细胞(innate lymphoid cell, ILC, 也译作先天淋巴细胞)的免疫细胞通过发育逐渐地为对感

深度解析免疫细胞和干细胞之间的作用机制 助力干细胞再生疗法的开发

我们可能会认为自己是静态的生物,但实际上我们机体的细胞处于持续的流动之中,机体皮肤和肠道的外层组织每隔几周都会被替换,红细胞在替换之前都会在机体中循环大约100天,而肝脏和脂肪细胞往往寿命较长,每一个肝脏细胞都可以生存超过1年时间,而脂肪细胞的平均寿命为10年,在我们一生过程中这些细胞会反复地替换更新,在个体正常的一生中有大约一半的心脏细胞都会被替换;当健康组织因受伤而缺失时,新生细胞就会去修

JCI:是真的吗?细菌可引发1型糖尿病!

近日,一项刊登于国际杂志The Journal of Clinical Investigation上的研究论文中,来自卡迪夫大学的研究人员通过研究发现,细菌或可通过诱发机体免疫系统破坏产胰岛素的细胞在1型糖尿病的发病过程中扮演重要角色;此前研究人员发现,杀伤性T细胞可以通过破坏胰腺β细胞来导致1型糖尿病的发生。

EMBO J:揭示特殊蛋白驱动免疫细胞自杀的分子机理

对于某些病原体而言,攻击或许是最好的防御,其会进入到人类机体的免疫细胞中,然而如果在隐藏的环境中这些病原体没有被检测到,那么受感染的细胞就会自我毁灭从而使得病原体被暴露出来;近日一项刊登于国际杂志EMBO Journal上的一篇研究报告中,来自巴塞尔大学等机构的研究人员通过研究发现,一种名为gasdermin的蛋白质可以在细胞膜中形成可渗透的孔状结构,从而诱发免疫细胞自杀。隐藏的最佳地点通常都是敌

Cell:细菌如何诱发机体致命性败血症的发生?

图片来源:medicalxpress.com 某些细菌性感染会引发机体败血症的发生,而败血症是一种危及生命的级联炎性和细胞死亡反应,该疾病非常难以治愈,近日刊登在国际杂志Cell上的一项研究论文中,来自康州大学的研究人员通过研究揭示了革兰氏阴性菌如何诱发机体出现败血症。 细菌通常不出现在血液中,一旦其进入血液中机体就会出现巨大的反应,而一旦细菌开始入侵血液中的细胞时,机体的免疫反应就会更

Nat Cell Biol:改造“腐化”免疫细胞为免疫系统攻击肿瘤发送信号

在癌症治疗过程中一个主要障碍在于肿瘤能够"策反"身体的免疫细胞,让它们为癌细胞干活。来自EPFL的研究人员最近发现了一种重新召回"腐化"免疫细胞的新方法,使其变为免疫系统攻击肿瘤的信号,甚至可以阻止癌症转移。   巨噬细胞是保护宿主防止病原体入侵的重要免疫细胞类型。但是在癌症病人体内,巨噬细胞能够被肿瘤"劫持",帮助维持肿瘤恶性生长和传播,这也是肿瘤免疫治疗所面临的一个重要问题。E